Cognition in hepatitis C patients treated with pegylated interferon

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 3, 2009, Pages 819-826

  Wobrock, Thomas ^a   Mihm, Ulrike ^b   Löhr, Caroline ^b   Hofmann, Wolf Peter ^c   Sarrazin, Christoph ^b,c   Zeuzem, Stefan ^b,c   Falkai, Peter ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Depression; Hepatitis C; Interferon ; Neurocognition; Neuropsychiatric side effects

Indexed keywords

AMANTADINE; LIVER ENZYME; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; MALE; MENTAL DISEASE; NEUROPSYCHIATRY; NEUROPSYCHOLOGICAL TEST; PSYCHOMOTOR PERFORMANCE; SCORING SYSTEM; SOCIAL INTERACTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; HOSPITALIZATION; MAJOR DEPRESSION; MIDDLE AGED;

ANTIVIRAL AGENTS; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYETHYLENE GLYCOLS; SEVERITY OF ILLNESS INDEX;

EID: 77949530685     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701714362     Document Type: Article

References (35)

1. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. 1961. An inventory for measuring depression. Arch Gen Psychiatry 4:53-63.
2. Davis GL, Esteban-Mur R, Rustgi V, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New Engl J Med 339:1493-1499. (Pubitemid 28543497)
3. Dieperink E, Willenbring M, Ho SB. 2000. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 157:867-876.
4. Dusheiko G. 1997. Side effects of alpha interferon in chronic hepatitis C. Hepatology 26(3 Suppl 1):112-121S.
5. Eberhardt G. 1994. Flimmerfrequenz-Analysator. Automatische Messmethode. Version 3.00. Modling, Austria: Dr G. Schuh-fried GmbH.
6. First MB, Spitzer RL, Gibbon M, Williams JBW 1998. Structured clinical interview for DSM-IV axis I disorders SCID I: clinical version 2.0. Rev. New York: Biometrics Research Department, New York State Psychiatric Institute.
7. Fontana RJ. 2000. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 18:107-116.
8. Fontana RJ, Bieliauskas LA, Back-Madruga C, et al. 2005. HALT-C Trial Group. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol 43:614-622.
9. Forton DM, Taylor-Robinson SD, Thomas HC. 2006. Central nervous system changes in hepatitis C virus infection. Eur J Gastroenterol Hepatol 18:333-338.
10. Goldman HH, Skodal AE, Lave TR. 1992. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 149:1148-1156.
11. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
12. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
13. Hilsabeck RC, Perry W, Hassanein TI. 2002. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 35:440-446.
14. Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W 2005. Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc 11:16-22.
15. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. 2003. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 64:708-714.
16. Kraus MR, Schafer A, Csef H, Scheurlen M. 2005a. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 11:1769-1774.
17. Kraus MR, Schafer A, Wissmann S, Reimer P, Scheurlen M. 2005b. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther 77:90-100.
18. Laux, L, Glanzmann P, Schaffner P, Spielberger CD. 1981. Das State-Trait-Angstinventar. Weinheim: Beltz.
19. Lehrl S. 1977. Mehrfachwahl-Wortschatz-Intelligenztest. B-Version. Erlangen: Straube.
20. Lieb K, Engelbrecht MA, Gut O, et al. 2006. Cognitive impairment in patients with chronic hepatitis treated with interferon alpah (IFNalpha): results from a prospective study. Eur Psychiatry 21:204-210.
21. Licinio J, Kling MA, Hauser P. 1998. Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol 25:30-38.
22. Manns MP, McHutchison JG, Gordon SC, et al. 2001. Peginter-feron alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
23. McAndrews MP, Farcnik K, Carlen P, et al. 2005. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 41:801-808.
24. McHutchison JG, Gordon SC, Schiff ER, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl J Med 339: 1485-1492.
25. Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br. J Psychiatry 134:382-389.
26. Norusis MJ. 2000. SPSS 10.0 Guide to Data Analysis. Englewood Cliffs, NJ: Prentice Hall.
27. Raisson CL, Borisov AS, Broadwell DS, et al. 2005. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 66:41-48
28. Reichenberg A, Gorman JM, Dieterich DT. 2005. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 19(Suppl 3):S174-178.
29. Reitan RM. 1958. The relation of the trail making test to organic brain damage. J Cons Psychol 19:393-394.
30. Renault PF, Hoofnagle JH, Park Y, et al. 1987. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 147:1577-1580.
31. Smith A, Tyrrell D, Coyle K, Higgins P. 1988. Effects of interferon alpha on performance in man: a preliminary report. Psychopharmacology (Berlin) 96:414-416
32. Smith JM, Misiak H. 1976. Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects-a review. Psychopharmacology 47:175-182.
33. Vienna test system (WINWTS). 1999. Version 4.50. Modling, Austria: Dr G. Schuhfried GmbH.
34. Weissenborn K, Ennen JC, Bokemeyer M, et al. 2006. Mono-aminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut, Epub ahead of print.
35. Zeuzem S, Heathcote JE, Martin N, Nieforth K, Modi M. 2001. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin Invest Drugs 10:2201-2213.